Navigation Links
GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Date:10/29/2010

tional funding to complete all of our studies and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans, including achievement of development and commercialization milestone payments and sales royalties under our collaboration with GlaxoSmithKline . In addition, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2009. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

GSK's cautionary statement regarding forward-looking statementsUnder the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2009.Registered in England & Wales:

No. 3888792Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GSFOLD –G


'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... NEW PROVIDENCE, N.J. , Sept. 16, 2014 ... a paper on the critical elements of installing and ... deliver systems at the American Society of Plumbing Engineers ... the Chicago Sheraton Hotel and Towers in ... West , program manager of Hospital Services for Linde ...
(Date:9/16/2014)... LONDON and BOSTON , September ... its Chief Scientific Officer, Fiona Marshall , will give ...   G protein-coupled receptors using StaR ® ... " Advances in Drug Discovery and Development " virtual symposium ... American Chemical Society. The virtual symposium is on Wednesday, 24 ...
(Date:9/15/2014)... and NEW YORK , ... Pharnext SAS and the Hereditary Neuropathy Foundation (HNF) announced ... the awareness around Charcot-Marie-Tooth (CMT) disease and support the ... Pharnext will provide financial support to ... and development of a specific section in the HNF ...
Breaking Medicine Technology:Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
... (NYSE: BSX ) will webcast its conference call ... 2011 on Thursday, July 28, at 8:00 a.m. ET. ... and Chief Executive Officer, and Jeff Capello, Executive Vice President ... the discussion will be available via Boston Scientific,s website.  Webcast ...
... July 14, 2011 /PRNewswire-Asia/ -- Owing to high-pressure life, ... fast food instead of traditional cooking, meanwhile, less and ... disadvantageous factors have affected people,s health . To ... just as its name implies, are the instruments used ...
Cached Medicine Technology:Boston Scientific to Webcast Conference Call Discussing Second Quarter 2011 Financial Results 2To Find the Key to Healthy Life 2
(Date:9/16/2014)... QuickMedical, a national leader in the ... veteran-owned small business has officially launched three new ... Nipro Medical, and CP Medical Sutures. , ... best, most affordable medical equipment and supplies. To ... effort to reach new medical facilities, QuickMedical has ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 True Science Cosmetics, ... lip gloss that true-ly pampers lips from the inside out ... all day. , “The creation of true lipz™ came about ... dry, dehydrated lips no matter what products we used. ... looked great on, but could actually hydrate and moisturize throughout ...
(Date:9/16/2014)... New Jersey (PRWEB) September 16, 2014 ... healthbeautydistributors.com, the drug-free, FDA approved Cefaly device for chronic ... 2014 for sales in the United States. Until now, ... with the manufacturer located in Belgium and wait 2-3 ... is located in the United States and once prescription ...
(Date:9/16/2014)... peep-toe shoe is a woman's shoe (usually a pump, ... which there is an opening at the toe-box which ... beginning in the 1940s, but disappeared by the 1960s. ... before falling out of fashion by the mid-1990s. More ... such as "peep-toe boots" appearing. After months of preparation ...
(Date:9/15/2014)... Club wear is provocative, revealing, or fetish clothing that is ... relaxed dress code. There are various types of clothing items ... of the club, the club's dress code and the weather. ... delightedly pronounced its new series of delicate club wears; all ... A nightclub (also known as a discothèque, or simply a ...
Breaking Medicine News(10 mins):Health News:True Science Cosmetics, LLC Launches True Lipz™ 2Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:Nice Peep Toes Are For Sale At Fecbek.com 2Health News:Delicate Club Wears Are For Sale At Fecbek.com 2
... you that already! Older adults are more ... shared or not shared information with, according to a new ... the kind of memory faux pas that can lead to ... doctor,s office. Ironically, after making these memory errors older adults ...
... HealthDay Reporter , MONDAY, Aug. 30 (HealthDay ... pain in patients with nerve pain stemming from injuries ... with chronic nerve pain were taught to take a ... pipe, three times a day, for five days. The ...
... Quebec, Australia and the United Kingdom by publicly ... CMAJ ( Canadian Medical Association Journal ) (pre-embargo ... million Canadians (19% of the population) currently use ... recent years. A 2009 review of studies indicates ...
... 30 August 2010 - The notion that cutting or ... difficult to understand for most people, but it is ... themselves. Individuals with borderline personality disorder experience ... regulation skills. This group of people also displays high ...
... heart rhythm disorder is resulting in an alarming number ... A research team led by Professor Prash Sanders, ... Centre at the Royal Adelaide Hospital, found that hospital ... in Australia over a 15-year period. These findings ...
... Elsevier, a world-leading publisher of scientific, technical ... the launch of SciVerse, an innovative platform that ... scientific community to collaborate on the development of ... to releasing the APIs (application programming interfaces) for ...
Cached Medicine News:Health News:Older adults experience 'destination amnesia' 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Hurts so good -- neural clues to the calming effects of self-harm 2Health News:Heart disorder hits national epidemic proportions 2Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: